This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mazur, W. Articles by Spencer, W. H. Search for Related Content PubMed PubMed Citation Articles by Mazur, W. Articles by Spencer, W. H., III Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiomyopathy Hazardous Substances DB ETHANOL Related Collections Myocardial cardiomyopathy disease Echocardiography

(Circulation. 2001;103:1492.)
© 2001 American Heart Association, Inc.

Brief Rapid Communications

Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy

Wojciech Mazur, MD; Sherif F. Nagueh, MD; Nasser M. Lakkis, MD; Katherine J. Middleton, RCT; Donna Killip, RN; Robert Roberts, MD; William H. Spencer, III, MD

From the Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, Tex.

Correspondence and reprint requests to Sherif F. Nagueh, MD, Section of Cardiology, 6550 Fannin St, SM-1246, Houston, TX 77030-2717. E-mail sherifn{at}bcm.tmc.edu

Background—Hypertrophic obstructive cardiomyopathy (HOCM) is characterized by left ventricular hypertrophy (LVH) in the absence of increased external load. Recently, nonsurgical septal reduction therapy (NSRT) with intracoronary ethanol has been introduced to treat severely symptomatic patients with outflow tract obstruction. Its long-term effects on LV mass, however, are unknown.

Methods and Results—The LV size, function, and outflow tract gradient of 26 HOCM patients (53±15 years old) who underwent NSRT were assessed by echocardiography at baseline and 1 and 2 years after the procedure. LVH was evaluated by wall thickness of individual myocardial segments, planimetered myocardial area, and mass. The outflow gradient decreased from 36±6 mm Hg before NSRT to 0±3 mm Hg at 2 years (P<0.001), with patients experiencing symptomatic improvement (P<0.05). LV end-diastolic and end-systolic dimensions increased significantly at both 1 and 2 years (P<0.001). All parameters of LVH showed evidence of regression. LV mass decreased (301±78 g at baseline, 223±5 g at 1 year, and 190±58 g at 2 years; P<0.01), with the 2-year reduction in mass related to infarct size and the acute reduction in outflow tract gradient (r=0.48, P<0.05 and r=0.63, P<0.01, respectively).

Conclusions—NSRT results in LV remodeling that is characterized by an increase in LV size and a decrease in the extent of LVH.

Key Words: hypertrophy • cardiomyopathy • remodeling

This article has been cited by other articles:

				G S Soor, A Luk, E Ahn, J R Abraham, A Woo, A Ralph-Edwards, and J Butany Hypertrophic cardiomyopathy: current understanding and treatment objectives J. Clin. Pathol., March 1, 2009; 62(3): 226 - 235. [Abstract] [Full Text] [PDF]

				F. A. Cuoco, W. H. Spencer III, V. L. Fernandes, C. D. Nielsen, S. Nagueh, J. L. Sturdivant, R. B. Leman, J. M. Wharton, and M. R. Gold Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Sudden Death After Alcohol Septal Ablation of Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., November 18, 2008; 52(21): 1718 - 1723. [Abstract] [Full Text] [PDF]

				L. A. Malek, L. Chojnowska, M. Klopotowski, R. Maczynska, M. Demkow, A. Witkowski, B. Kusmierczyk, E. Piotrowicz, M. Konka, M. Dabrowski, et al. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation Eur J Heart Fail, November 1, 2008; 10(11): 1123 - 1126. [Abstract] [Full Text] [PDF]

				V. L. Fernandes, C. Nielsen, S. F. Nagueh, A. E. Herrin, C. Slifka, J. Franklin, and W. H. Spencer III Follow-Up of Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy: The Baylor and Medical University of South Carolina Experience 1996 to 2007 J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 561 - 570. [Abstract] [Full Text] [PDF]

				P. Sorajja, U. Valeti, R. A. Nishimura, S. R. Ommen, C. S. Rihal, B. J. Gersh, D. O. Hodge, H. V. Schaff, and D. R. Holmes Jr Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy Circulation, July 8, 2008; 118(2): 131 - 139. [Abstract] [Full Text] [PDF]

				M. W. Hansen and N. Merchant MRI of Hypertrophic Cardiomyopathy: Part 2, Differential Diagnosis, Risk Stratification, and Posttreatment MRI Appearances Am. J. Roentgenol., December 1, 2007; 189(6): 1344 - 1352. [Abstract] [Full Text] [PDF]

				E. W. Daw, S. N. Chen, G. Czernuszewicz, R. Lombardi, Y. Lu, J. Ma, R. Roberts, S. Shete, and A. J. Marian Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy Hum. Mol. Genet., October 15, 2007; 16(20): 2463 - 2471. [Abstract] [Full Text] [PDF]

				M. A. Fifer Most Fully Informed Patients Choose Septal Ablation Over Septal Myectomy Circulation, July 10, 2007; 116(2): 207 - 216. [Full Text] [PDF]

				D. S. Jassal, T. G. Neilan, M. A. Fifer, I. F. Palacios, P. A. Lowry, G. J. Vlahakes, M. H. Picard, and D. M. Yoerger Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy Eur. Heart J., August 1, 2006; 27(15): 1805 - 1810. [Abstract] [Full Text] [PDF]

				H. Dokainish and N. Lakkis Alcohol relaxes the stiff heart Eur. Heart J., August 1, 2006; 27(15): 1769 - 1770. [Full Text] [PDF]

				R. Roberts and U. Sigwart Current Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy Circulation, July 12, 2005; 112(2): 293 - 296. [Full Text] [PDF]

				W. G. van Dockum, A. M. Beek, F. J. ten Cate, J. M. ten Berg, O. Bondarenko, M. J.W. Gotte, J. W.R. Twisk, M. B.M. Hofman, C. A. Visser, and A. C. van Rossum Early Onset and Progression of Left Ventricular Remodeling After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Circulation, May 17, 2005; 111(19): 2503 - 2508. [Abstract] [Full Text] [PDF]

				S. J. Deb, H. V. Schaff, J. A. Dearani, R. A. Nishimura, and S. R. Ommen Septal Myectomy Results in Regression of Left Ventricular Hypertrophy in Patients With Hypertrophic Obstructive Cardiomyopathy Ann. Thorac. Surg., December 1, 2004; 78(6): 2118 - 2122. [Abstract] [Full Text] [PDF]

				F H Gietzen, C J Leuner, L Obergassel, C Strunk-Mueller, and H Kuhn Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients Heart, June 1, 2004; 90(6): 638 - 644. [Abstract] [Full Text] [PDF]

				S. M. Chang, N. M. Lakkis, J. Franklin, W. H. Spencer III, and S. F. Nagueh Predictors of Outcome After Alcohol Septal Ablation Therapy in Patients With Hypertrophic Obstructive Cardiomyopathy Circulation, February 24, 2004; 109(7): 824 - 827. [Abstract] [Full Text] [PDF]

				W. G. van Dockum, F. J. ten Cate, J. M. ten Berg, A. M. Beek, J. W. R. Twisk, J. Vos, M. B. M. Hofman, C. A. Visser, and A. C. van Rossum Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging J. Am. Coll. Cardiol., January 7, 2004; 43(1): 27 - 34. [Abstract] [Full Text] [PDF]

				B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713. [Full Text] [PDF]

				Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991. [Full Text] [PDF]

				S. M. Chang, S. F. Nagueh, W. H. Spencer III, and N. M. Lakkis Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy J. Am. Coll. Cardiol., July 16, 2003; 42(2): 296 - 300. [Abstract] [Full Text] [PDF]

				S. Steinbis Hypertrophic Obstructive Cardiomyopathy and Septal Ablation Crit. Care Nurse, June 1, 2003; 23(3): 47 - 50. [Full Text] [PDF]

				A. J.S. Coats, M. Henein, M. Flather, U. Sigwart, H. Seggewiss, D. Wang, M. Yousufuddin, and W. Shamim Retraction: Shamim et Al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 2002;347:1326-33. N. Engl. J. Med., March 6, 2003; 348(10): 951 - 951. [Full Text] [PDF]

				W. Shamim, M. Yousufuddin, D. Wang, M. Henein, H. Seggewiss, M. Flather, A. J.S. Coats, and U. Sigwart Nonsurgical Reduction of the Interventricular Septum in Patients with Hypertrophic Cardiomyopathy N. Engl. J. Med., October 24, 2002; 347(17): 1326 - 1333. [Abstract] [Full Text] [PDF]

				F. Cecchi, I. Olivotto, R. Roberts, and U. Sigwart New Concepts in Hypertrophic Cardiomyopathies * Response Circulation, June 11, 2002; 105 (23): e188 - e188. [Full Text] [PDF]

				B. J. Maron Hypertrophic Cardiomyopathy: A Systematic Review JAMA, March 13, 2002; 287(10): 1308 - 1320. [Abstract] [Full Text] [PDF]

				S. F. Nagueh, S. R. Ommen, N. M. Lakkis, D. Killip, W. A. Zoghbi, H. V. Schaff, G. K. Danielson, M. A. Quinones, A. J. Tajik, and W. H. Spencer III Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1701 - 1706. [Abstract] [Full Text] [PDF]

				R. Roberts and U. Sigwart New Concepts in Hypertrophic Cardiomyopathies, Part II Circulation, October 30, 2001; 104(18): 2249 - 2252. [Full Text] [PDF]

				U. Sigwart Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy Eur. Heart J. Suppl., October 1, 2001; 3(suppl_L): L38 - L42. [Abstract] [PDF]

				Septal Ablation for HOCM Reduces LV Hypertrophy Journal Watch Cardiology, May 18, 2001; 2001(518): 4 - 4. [Full Text]